© 2005 European Society for Medical Oncology
Original article |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy
Departments of 1 Clinical Therapeutics and 2 Radiology, Medical School, University of Athens, Athens, Greece
* Correspondence to: Dr A. Bamias, 31 Komninon St, Haidari, 124 62 Athens, Greece. Tel: +30-210-3381546; Fax: +30-210-3381511; Email: abamias{at}med.uoa.gr
Background: The majority of patients with advanced urothelial cancer are elderly, but data regarding this specific age group are limited. We compared the tolerability and efficacy of first-line platinum (cisplatin or carboplatin)-based chemotherapy in elderly patients (
70 years) with those in younger patients.
Patients and methods: A total of 381 patients with advanced urothelial carcinoma received CIMV (cisplatin, ifosphamide, methotrexate, vinblastine) (n=32), MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) (n=105), DC (docetaxel, cisplatin) (n=174), CaG (carboplatin, gemcitabine) (n=64) or other regimes (n=6) and were included in this analysis.
Results: A total of 116 patients were 70 years. Elderly patients experienced more frequent neutropenia grade 3/4 (55% versus 37%, P=0.087) and renal toxicity (28% versus 10%, P=0.033) among patients treated with CIMV/MVAC, and neutropenic infections (4% versus 0%, P=0.019) among patients treated with DC. Median survival did not differ significantly between elderly and younger patients (9.3 versus 10.5 months, P=0.16). Eastern Cooperative Oncology Group performance status (PS) and haemoglobin were independently associated with prognosis. Patients with PS <2 and haemoglobin 10 g/dl had a median survival of 14 months as opposed to 5 months for patients with PS 2 or haemoglobin <10 g/dl (P <0.001).
Conclusion: Elderly patients with advanced urothelial cancer tolerate platinum-based chemotherapy well and derive the same benefit as their younger counterparts.
Key words: bladder cancer, chemotherapy, elderly, platinum
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. V. Raj, A. Iasonos, H. Herr, and S. M. Donat Formulas Calculating Creatinine Clearance Are Inadequate for Determining Eligibility for Cisplatin-Based Chemotherapy in Bladder Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3095 - 3100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]
|
|